Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 4
1970 4
1971 1
1972 7
1973 2
1974 2
1975 6
1976 11
1977 5
1978 9
1979 8
1980 6
1981 6
1982 2
1983 6
1984 16
1985 16
1986 12
1987 17
1988 7
1989 10
1990 12
1991 25
1992 16
1993 24
1994 20
1995 9
1996 18
1997 29
1998 31
1999 27
2000 26
2001 28
2002 25
2003 21
2004 31
2005 29
2006 27
2007 12
2008 21
2009 12
2010 7
2011 12
2012 3
2013 4
2015 1
2016 5
2017 3
2018 3
2019 3
2020 1
2021 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

630 results

Results by year

Filters applied: . Clear all
Page 1
Range of antinuclear antibodies in "healthy" individuals.
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Tan EM, et al. Among authors: kalden jr. Arthritis Rheum. 1997 Sep;40(9):1601-11. doi: 10.1002/art.1780400909. Arthritis Rheum. 1997. PMID: 9324014
What triggers anti-dsDNA antibodies?
Herrmann M, Zoller OM, Hagenhofer M, Voll R, Kalden JR. Herrmann M, et al. Among authors: kalden jr. Mol Biol Rep. 1996;23(3-4):265-7. doi: 10.1007/BF00351179. Mol Biol Rep. 1996. PMID: 9112239 Review.
Emerging Therapies for Rheumatoid Arthritis.
Kalden JR. Kalden JR. Rheumatol Ther. 2016 Jun;3(1):31-42. doi: 10.1007/s40744-016-0032-4. Epub 2016 Jun 3. Rheumatol Ther. 2016. PMID: 27747522 Free PMC article. Review.
Treatment of rheumatoid arthritis in the third millennium.
Skapenko A, Kalden JR, Schulze-Koops H. Skapenko A, et al. Among authors: kalden jr. Scand J Rheumatol. 2001;30(5):249-54. doi: 10.1080/030097401753180309. Scand J Rheumatol. 2001. PMID: 11727837 Review.
Retrovirus-associated rheumatic syndromes.
Herrmann M, Neidhart M, Gay S, Hagenhofer M, Kalden JR. Herrmann M, et al. Among authors: kalden jr. Curr Opin Rheumatol. 1998 Jul;10(4):347-54. doi: 10.1097/00002281-199807000-00012. Curr Opin Rheumatol. 1998. PMID: 9725097 Review.
Controversies in COX-2 selective inhibition.
Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, García Rodríguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Willaims GH. Simon LS, et al. Among authors: kalden jr. J Rheumatol. 2002 Jul;29(7):1501-10. J Rheumatol. 2002. PMID: 12136912 Review. No abstract available.
Perspectives for TNF-alpha-targeting therapies.
Lorenz HM, Kalden JR. Lorenz HM, et al. Among authors: kalden jr. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S17-24. doi: 10.1186/ar564. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110119 Free PMC article. Review.
Lefunomide in combination therapy.
Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC. Kalden JR, et al. J Rheumatol Suppl. 2004 Jun;71:25-30. J Rheumatol Suppl. 2004. PMID: 15170905 Review.
SLE--a disease of clearance deficiency?
Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR, Herrmann M. Munoz LE, et al. Among authors: kalden jr. Rheumatology (Oxford). 2005 Sep;44(9):1101-7. doi: 10.1093/rheumatology/keh693. Epub 2005 May 31. Rheumatology (Oxford). 2005. PMID: 15928001 Review.
630 results